10. December 2012
End of Year Discount on Zedira products - Transglutaminase Newsletter 7-2012
Document

01. October 2012
(German Article) Entwicklung eines Zöliakie-Medikaments in Deutschland
Document

20. September 2012
Meet Zedira at the International Factor XIII Workshop in Debrecen, Hungary. Please contact us via e-mail to make an appointment.
Document

30. July 2012
Highlights in celiac disease and blood coagulation - Transglutaminase Newsletter 5-2012
Document

20. July 2012
New website online - Transglutaminase Newsletter 4-2012
Document

04. July 2012
Meet Zedira at the XXIInd International Fibrinogen Workshop in Brighton, UK. Please contact us via e-mail to make an appointment. Zedira presents an interesting scientific poster at the workshop.
Document

23. June 2012
Zedira, Dr. Falk Pharma and the University of Mainz Hospital, which together comprise a flagship project of the CI3 excellence cluster, are to receive subsidy funding for clinical development of a celiac disease drug.
Document

23. June 2012
Zedira, Dr. Falk Pharma und das Universitätsklinikum Mainz erhalten als Leuchtturmprojekt des Spitzenclusters CI3 Fördermittel für die klinische Entwicklung eines Zöliakie-Medikamentes.
Document

30. April 2012
Create your own Clotting-Assay - transglutaminase newsletter 3-2012
Document

28. February 2012
Microbial Transglutaminase Assay Kit - transglutaminase newsletter 2-2012
Document

01. February 2012
Meet Zedira at 56. Jahrestagung der Gesellschaft für Thrombose- und Hämostaseforschung (GTH), Associations of Haemostasis and Thrombosis, from 1–4 February 2012 in St. Gallen, Switzerland.
Document

01. January 2012
Zedira's Transglutaminase Newsletter January 2012 - Start into the New Year with our novel antibodies!
Document

Products

  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.

News  

  • Zedira publication: Microbial Transglutaminase Used in Bread Preparation at Standard Bakery Concentrations Does Not Increase Immunodetectable Amounts of Deamidated Gliadin
  • Pressemitteilung: Dr. Falk Pharma und Zedira geben den Abschluss der Phase 1b-Studie für ZED1227 zur Zöliakie-Therapie bekannt und planen Start der Wirksamkeitsstudie
  • Press release: Dr. Falk Pharma and Zedira announce completion of phase 1b clinical trial of ZED1227 for the treatment of celiac disease and move on to proof of concept study
  • Press Release: Dr. Falk Pharma GmbH and Zedira enter a phase 1b clinical trial for a celiac disease drug
  • Zedira publication: Microbial transglutaminase has a lower deamidation preference than human tissue transglutaminase on a celiac disease relevant wheat gliadin T-cell epitope
  • Press release: Additional subsidy funding for clinical development of a celiac disease drug
  • Pressemitteilung: Zusätzliche Fördermittel für die klinische Entwicklung eines Zöliakie-Medikamentes
  • Press Release: Cooperation between Zedira and Cardiff University - Transglutaminase 6 is the focus of new research into ataxia
  • Press Release: Dr. Falk Pharma and Zedira enter phase I clinical trials for a celiac disease drug
  • Press release: Zedira receives further funding to develop Factor XIIIa-blockers for safe anticoagulation

Blog  

Events  

  • MEDICA

    13.11.2017 - 16.11.2017
    Düsseldorf, Germany

  • Gordon Research Conference on: Transglutaminases in Human Disease Processes

    16.06.2018 - 17.06.2018
    Les Diablerets, Switzerland